- Published on
Emergency and Acute Medicine – Cor Pulmonale
Definition and Pathophysiologic Overview
Cor pulmonale refers to right ventricular hypertrophy or dilation caused by elevated pulmonary artery pressure. Right ventricular hypertrophy resulting from primary left-sided heart disease or congenital cardiac abnormalities is not classified as cor pulmonale. The disorder may be acute or chronic, depending on the rapidity and duration of pulmonary hypertension and the adaptive capacity of the right ventricle.
Acute cor pulmonale is marked by sudden right ventricular dilation with thinning and stretching of the ventricular wall, caused by an abrupt increase in right ventricular afterload due to acute pulmonary hypertension. The most common cause is a massive pulmonary embolism. Chronic cor pulmonale develops from long-standing pulmonary hypertension and is characterized initially by right ventricular hypertrophy, followed by dilation and eventual right-sided heart failure. This chronic form most often results from persistent alveolar hypoxia and represents an adaptive response to sustained elevation in pulmonary vascular resistance.
The pulmonary circulation is normally a low-pressure, low-resistance system with thin-walled, distensible arteries. Mean pulmonary arterial pressure typically ranges from 12 to 15 mm Hg, while normal left atrial pressure is approximately 6 to 10 mm Hg, resulting in a small pressure gradient of 6 to 9 mm Hg to drive pulmonary blood flow. Pulmonary arterial pressure is determined by cardiac output, pulmonary venous pressure, and pulmonary vascular resistance. Pulmonary hypertension may arise from markedly increased cardiac output, left-to-right shunts due to congenital heart disease, or most commonly hypoxia. Hypoxic pulmonary vasoconstriction is an adaptive response to alveolar hypoxia that preserves ventilation–perfusion matching by increasing pulmonary arterial pressure to maintain flow through the pulmonary vascular bed. Pulmonary embolism produces a similar effect by increasing resistance to pulmonary blood flow, while increased blood viscosity or elevated intrathoracic pressure can further impair pulmonary circulation.
Pulmonary hypertension is categorized into five groups. Group 1 includes pulmonary arterial hypertension. Group 2 consists of pulmonary hypertension due to left-sided heart disease, in which associated right ventricular dysfunction is not considered cor pulmonale. Group 3 includes pulmonary hypertension due to lung disease and/or hypoxia. Group 4 encompasses chronic thromboembolic pulmonary hypertension. Group 5 includes pulmonary hypertension with unclear or multifactorial mechanisms.
Epidemiology
Approximately 86,000 deaths occur annually from chronic obstructive pulmonary disease, with associated right ventricular failure contributing significantly in many cases. Cor pulmonale accounts for 10–30% of heart failure admissions in the United States. Among patients older than 50 years with COPD, about half develop pulmonary hypertension and are therefore at risk for cor pulmonale. Disease progression is closely tied to the severity of the underlying pulmonary disorder, and once cor pulmonale develops, the estimated five-year survival rate is approximately 30%.
Etiology
Chronic hypoxia is the most frequent cause of cor pulmonale and may result from COPD, residence at high altitude, obstructive sleep apnea, or chest wall deformities such as kyphoscoliosis. Other causes include pulmonary embolism and interstitial lung diseases such as scleroderma, systemic lupus erythematosus, mixed connective tissue disease, sarcoidosis, pulmonary Langerhans cell histiocytosis, neurofibromatosis, lymphangioleiomyomatosis, and cystic fibrosis. Additional contributing factors include severe anemia, obesity, pulmonary veno-occlusive disease, pulmonary vascular obstruction from tumors or lymphadenopathy, increased blood viscosity as seen in polycythemia vera or leukemia, and elevated intrathoracic pressure due to mechanical ventilation with positive end-expiratory pressure. Idiopathic primary pulmonary hypertension is a less common cause.
Clinical Manifestations
Patients frequently present with exertional dyspnea, easy fatigability, weakness, and reduced exercise tolerance. Additional symptoms include exertional syncope, cough, hemoptysis, and exertional angina even in the absence of coronary artery disease. Anorexia, right upper quadrant discomfort, wheezing, hoarseness, and weight gain may occur as right-sided heart failure progresses. Signs of volume overload include hepatomegaly, ascites, and peripheral edema. In advanced disease, cardiogenic shock may develop, manifested by oliguria, cool extremities, and pulmonary edema resulting from interventricular septal displacement that impairs left ventricular diastolic filling.
History commonly reveals exercise intolerance, palpitations, chest pain, lightheadedness, syncope, and lower extremity swelling. Physical examination may show jugular venous distention with prominent A and V waves, increased chest diameter, crackles or wheezes on lung auscultation, and a left parasternal heave. Splitting of the second heart sound or murmurs related to pulmonary vasculature abnormalities may be present. A hepatojugular reflex, pulsatile liver, and pitting edema of the lower extremities are typical findings in advanced cases.
Diagnostic Evaluation
Pulse oximetry or arterial blood gas analysis typically demonstrates resting hypoxemia with arterial oxygen tensions of 40–60 mm Hg and resting carbon dioxide levels often between 40 and 70 mm Hg. Hematocrit is frequently elevated due to secondary polycythemia. Elevated B-type natriuretic peptide levels are sensitive for moderate to severe pulmonary hypertension and may independently predict mortality, although elevation alone is insufficient to establish the diagnosis of cor pulmonale. Other laboratory tests are generally of limited diagnostic value.
Chest radiography often reveals signs of pulmonary hypertension, including enlarged pulmonary arteries greater than 16–18 mm and an enlarged right ventricular silhouette. Although abnormalities are seen in more than 90% of patients, chest radiographs do not reliably indicate disease severity. Pleural effusions are not a feature of isolated cor pulmonale. Electrocardiography may demonstrate right-axis deviation, right bundle branch block, right ventricular hypertrophy with dominant R waves in leads V1 and V2, prominent S waves in leads V5 and V6, small R waves with deep S waves across the precordium, and right atrial enlargement with tall, peaked P waves consistent with P pulmonale. Acute cor pulmonale may show an S1Q3 pattern, transient hypoxia-related changes, and right precordial T-wave flattening.
Echocardiography is the preferred noninvasive diagnostic modality and may demonstrate right ventricular hypertrophy or dilation, tricuspid regurgitation, and Doppler-based estimation of pulmonary artery pressure and right ventricular ejection fraction. Chest computed tomography, ventilation–perfusion scanning, or pulmonary angiography are useful when acute cor pulmonale is suspected, particularly in cases of pulmonary embolism. Magnetic resonance imaging offers superior assessment of right ventricular size and function compared with echocardiography. Pulmonary function testing may reveal reduced diffusion capacity associated with pulmonary hypertension. Right-heart catheterization remains the most accurate method for assessing pulmonary vascular hemodynamics and provides precise measurements of pulmonary arterial and pulmonary capillary wedge pressures.
Differential Diagnosis
The differential diagnosis includes primary left-sided heart disease such as mitral stenosis, congenital heart disease including Eisenmenger syndrome with left-to-right shunting, hypothyroidism, and cirrhosis.
Management and Prehospital Care
Prehospital treatment is supportive and includes supplemental oxygen titrated to achieve arterial oxygen saturation of approximately 90%, establishment of intravenous access, continuous cardiac monitoring, and pulse oximetry. Bronchospasm related to underlying respiratory disease should be treated with beta-agonist nebulizers. Vasodilators and diuretics have no role in the prehospital setting. Patients with severe hypoxia may require endotracheal intubation.
Emergency Department Treatment
Management in the emergency department is directed at treating the underlying disease process and reducing pulmonary hypertension. Supplemental oxygen should be administered to raise arterial oxygen saturation to 90%, thereby reducing pulmonary vasoconstriction and right ventricular afterload while improving cardiac output and promoting diuresis. Careful monitoring of ventilation and carbon dioxide levels is essential, as hypercapnia may suppress respiratory drive and worsen acidosis. Diuretics such as furosemide may be used cautiously to reduce circulating blood volume and pulmonary artery pressure, with close attention to avoiding hypovolemia and electrolyte disturbances. Patients should be maintained on salt and fluid restriction. Digoxin has no role in the treatment of cor pulmonale.
Bronchodilator therapy is particularly beneficial in patients with COPD, as it reduces ventricular afterload and improves airflow. Selective beta-adrenergic agents such as subcutaneous terbutaline may be administered, and theophylline may be considered to enhance diaphragmatic contractility and reduce muscle fatigue. Anticoagulation should be considered in patients at high risk for thromboembolic disease. In acutely decompensated COPD, early initiation of corticosteroids and antibiotics is indicated. Improvement of the underlying respiratory disorder typically results in improved right ventricular function.
Medications
Furosemide may be administered at doses of 20–60 mg intravenously in adults, with pediatric dosing starting at 1 mg/kg and titrated as needed to a maximum of 6 mg/kg. Terbutaline may be administered at a dose of 0.25 mg subcutaneously.
Disposition and Follow-Up
Hospital admission is indicated for patients with new-onset hypoxia, anasarca, severe respiratory failure, or when required by the severity of the underlying disease. Patients without hypoxia or with stable oxygen requirements may be considered for discharge. Close outpatient follow-up is essential once the underlying etiology has responded to acute management, and evaluation for sleep apnea with a sleep study should be coordinated by the patient’s physician when indicated. Home oxygen therapy should be ensured for patients with chronic hypoxia.
Key Clinical Insights and Common Management Errors
Physical examination findings may be unreliable in patients with COPD because chest hyperinflation often obscures classic signs of cor pulmonale. Vasodilator therapy should be reserved for cases in which conventional management and adequate oxygenation have failed and should be used with caution.
Definition and Pathophysiologic Overview
Cor pulmonale refers to right ventricular hypertrophy or dilation caused by elevated pulmonary artery pressure. Right ventricular hypertrophy resulting from primary left-sided heart disease or congenital cardiac abnormalities is not classified as cor pulmonale. The disorder may be acute or chronic, depending on the rapidity and duration of pulmonary hypertension and the adaptive capacity of the right ventricle.
Acute cor pulmonale is marked by sudden right ventricular dilation with thinning and stretching of the ventricular wall, caused by an abrupt increase in right ventricular afterload due to acute pulmonary hypertension. The most common cause is a massive pulmonary embolism. Chronic cor pulmonale develops from long-standing pulmonary hypertension and is characterized initially by right ventricular hypertrophy, followed by dilation and eventual right-sided heart failure. This chronic form most often results from persistent alveolar hypoxia and represents an adaptive response to sustained elevation in pulmonary vascular resistance.
The pulmonary circulation is normally a low-pressure, low-resistance system with thin-walled, distensible arteries. Mean pulmonary arterial pressure typically ranges from 12 to 15 mm Hg, while normal left atrial pressure is approximately 6 to 10 mm Hg, resulting in a small pressure gradient of 6 to 9 mm Hg to drive pulmonary blood flow. Pulmonary arterial pressure is determined by cardiac output, pulmonary venous pressure, and pulmonary vascular resistance. Pulmonary hypertension may arise from markedly increased cardiac output, left-to-right shunts due to congenital heart disease, or most commonly hypoxia. Hypoxic pulmonary vasoconstriction is an adaptive response to alveolar hypoxia that preserves ventilation–perfusion matching by increasing pulmonary arterial pressure to maintain flow through the pulmonary vascular bed. Pulmonary embolism produces a similar effect by increasing resistance to pulmonary blood flow, while increased blood viscosity or elevated intrathoracic pressure can further impair pulmonary circulation.
Pulmonary hypertension is categorized into five groups. Group 1 includes pulmonary arterial hypertension. Group 2 consists of pulmonary hypertension due to left-sided heart disease, in which associated right ventricular dysfunction is not considered cor pulmonale. Group 3 includes pulmonary hypertension due to lung disease and/or hypoxia. Group 4 encompasses chronic thromboembolic pulmonary hypertension. Group 5 includes pulmonary hypertension with unclear or multifactorial mechanisms.
Epidemiology
Approximately 86,000 deaths occur annually from chronic obstructive pulmonary disease, with associated right ventricular failure contributing significantly in many cases. Cor pulmonale accounts for 10–30% of heart failure admissions in the United States. Among patients older than 50 years with COPD, about half develop pulmonary hypertension and are therefore at risk for cor pulmonale. Disease progression is closely tied to the severity of the underlying pulmonary disorder, and once cor pulmonale develops, the estimated five-year survival rate is approximately 30%.
Etiology
Chronic hypoxia is the most frequent cause of cor pulmonale and may result from COPD, residence at high altitude, obstructive sleep apnea, or chest wall deformities such as kyphoscoliosis. Other causes include pulmonary embolism and interstitial lung diseases such as scleroderma, systemic lupus erythematosus, mixed connective tissue disease, sarcoidosis, pulmonary Langerhans cell histiocytosis, neurofibromatosis, lymphangioleiomyomatosis, and cystic fibrosis. Additional contributing factors include severe anemia, obesity, pulmonary veno-occlusive disease, pulmonary vascular obstruction from tumors or lymphadenopathy, increased blood viscosity as seen in polycythemia vera or leukemia, and elevated intrathoracic pressure due to mechanical ventilation with positive end-expiratory pressure. Idiopathic primary pulmonary hypertension is a less common cause.
Clinical Manifestations
Patients frequently present with exertional dyspnea, easy fatigability, weakness, and reduced exercise tolerance. Additional symptoms include exertional syncope, cough, hemoptysis, and exertional angina even in the absence of coronary artery disease. Anorexia, right upper quadrant discomfort, wheezing, hoarseness, and weight gain may occur as right-sided heart failure progresses. Signs of volume overload include hepatomegaly, ascites, and peripheral edema. In advanced disease, cardiogenic shock may develop, manifested by oliguria, cool extremities, and pulmonary edema resulting from interventricular septal displacement that impairs left ventricular diastolic filling.
History commonly reveals exercise intolerance, palpitations, chest pain, lightheadedness, syncope, and lower extremity swelling. Physical examination may show jugular venous distention with prominent A and V waves, increased chest diameter, crackles or wheezes on lung auscultation, and a left parasternal heave. Splitting of the second heart sound or murmurs related to pulmonary vasculature abnormalities may be present. A hepatojugular reflex, pulsatile liver, and pitting edema of the lower extremities are typical findings in advanced cases.
Diagnostic Evaluation
Pulse oximetry or arterial blood gas analysis typically demonstrates resting hypoxemia with arterial oxygen tensions of 40–60 mm Hg and resting carbon dioxide levels often between 40 and 70 mm Hg. Hematocrit is frequently elevated due to secondary polycythemia. Elevated B-type natriuretic peptide levels are sensitive for moderate to severe pulmonary hypertension and may independently predict mortality, although elevation alone is insufficient to establish the diagnosis of cor pulmonale. Other laboratory tests are generally of limited diagnostic value.
Chest radiography often reveals signs of pulmonary hypertension, including enlarged pulmonary arteries greater than 16–18 mm and an enlarged right ventricular silhouette. Although abnormalities are seen in more than 90% of patients, chest radiographs do not reliably indicate disease severity. Pleural effusions are not a feature of isolated cor pulmonale. Electrocardiography may demonstrate right-axis deviation, right bundle branch block, right ventricular hypertrophy with dominant R waves in leads V1 and V2, prominent S waves in leads V5 and V6, small R waves with deep S waves across the precordium, and right atrial enlargement with tall, peaked P waves consistent with P pulmonale. Acute cor pulmonale may show an S1Q3 pattern, transient hypoxia-related changes, and right precordial T-wave flattening.
Echocardiography is the preferred noninvasive diagnostic modality and may demonstrate right ventricular hypertrophy or dilation, tricuspid regurgitation, and Doppler-based estimation of pulmonary artery pressure and right ventricular ejection fraction. Chest computed tomography, ventilation–perfusion scanning, or pulmonary angiography are useful when acute cor pulmonale is suspected, particularly in cases of pulmonary embolism. Magnetic resonance imaging offers superior assessment of right ventricular size and function compared with echocardiography. Pulmonary function testing may reveal reduced diffusion capacity associated with pulmonary hypertension. Right-heart catheterization remains the most accurate method for assessing pulmonary vascular hemodynamics and provides precise measurements of pulmonary arterial and pulmonary capillary wedge pressures.
Differential Diagnosis
The differential diagnosis includes primary left-sided heart disease such as mitral stenosis, congenital heart disease including Eisenmenger syndrome with left-to-right shunting, hypothyroidism, and cirrhosis.
Management and Prehospital Care
Prehospital treatment is supportive and includes supplemental oxygen titrated to achieve arterial oxygen saturation of approximately 90%, establishment of intravenous access, continuous cardiac monitoring, and pulse oximetry. Bronchospasm related to underlying respiratory disease should be treated with beta-agonist nebulizers. Vasodilators and diuretics have no role in the prehospital setting. Patients with severe hypoxia may require endotracheal intubation.
Emergency Department Treatment
Management in the emergency department is directed at treating the underlying disease process and reducing pulmonary hypertension. Supplemental oxygen should be administered to raise arterial oxygen saturation to 90%, thereby reducing pulmonary vasoconstriction and right ventricular afterload while improving cardiac output and promoting diuresis. Careful monitoring of ventilation and carbon dioxide levels is essential, as hypercapnia may suppress respiratory drive and worsen acidosis. Diuretics such as furosemide may be used cautiously to reduce circulating blood volume and pulmonary artery pressure, with close attention to avoiding hypovolemia and electrolyte disturbances. Patients should be maintained on salt and fluid restriction. Digoxin has no role in the treatment of cor pulmonale.
Bronchodilator therapy is particularly beneficial in patients with COPD, as it reduces ventricular afterload and improves airflow. Selective beta-adrenergic agents such as subcutaneous terbutaline may be administered, and theophylline may be considered to enhance diaphragmatic contractility and reduce muscle fatigue. Anticoagulation should be considered in patients at high risk for thromboembolic disease. In acutely decompensated COPD, early initiation of corticosteroids and antibiotics is indicated. Improvement of the underlying respiratory disorder typically results in improved right ventricular function.
Medications
Furosemide may be administered at doses of 20–60 mg intravenously in adults, with pediatric dosing starting at 1 mg/kg and titrated as needed to a maximum of 6 mg/kg. Terbutaline may be administered at a dose of 0.25 mg subcutaneously.
Disposition and Follow-Up
Hospital admission is indicated for patients with new-onset hypoxia, anasarca, severe respiratory failure, or when required by the severity of the underlying disease. Patients without hypoxia or with stable oxygen requirements may be considered for discharge. Close outpatient follow-up is essential once the underlying etiology has responded to acute management, and evaluation for sleep apnea with a sleep study should be coordinated by the patient’s physician when indicated. Home oxygen therapy should be ensured for patients with chronic hypoxia.
Key Clinical Insights and Common Management Errors
Physical examination findings may be unreliable in patients with COPD because chest hyperinflation often obscures classic signs of cor pulmonale. Vasodilator therapy should be reserved for cases in which conventional management and adequate oxygenation have failed and should be used with caution.
0 Comments
